33(top 2%)
papers
1.1K(top 2%)
citations
14(top 2%)
h-index
25(top 2%)
g-index
36
all documents
1.1K
doc citations
519
citing journals
26
times ranked

Top Articles

#TitleJournalYearCitations
1XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillationEuropean Heart Journal2016383
2GIDEON (Global Investigation of therapeutic DE cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysisInternational Journal of Clinical Practice2014215
3First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional studyInternational Journal of Clinical Practice2012102
4Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trialLancet Respiratory Medicine,the202185
5Regional differences in sorafenib‐treated patients with hepatocellular carcinoma: GIDEON observational studyLiver International201644
6Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosisPharmacogenomics Journal201336
7Perfusion CT in acute stroke: prediction of vessel recanalization and clinical outcome in intravenous thrombolytic therapyEuropean Radiology200735
8REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguatJournal of Heart and Lung Transplantation201829
9REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survivalJournal of Heart and Lung Transplantation201829
10Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT TrialTH Open202029
11Treatment of endometriosis in different ethnic populations: a meta-analysis of two clinical trialsBMC Women's Health201225
12Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access studyBMC Pulmonary Medicine201723
13Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndromeMultiple Sclerosis Journal201419
14Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON studyOncotarget201618
15The Three-Decade Long Journey in Heart Failure Drug DevelopmentHandbook of Experimental Pharmacology201612
16Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA)Annals of Medicine201812
17Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertensionJournal of Heart and Lung Transplantation20219
18Type I Interferon Receptor Expression in Human Pancreatic and Periampullary Cancer TissuePancreas20157
19Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertensionEuropean Respiratory Review20226
20Application of the REVEAL risk score calculator 2.0 in the PATENT studyInternational Journal of Cardiology20215
21Sorafenib treatment by Child–Pugh score in Latin American patients with hepatocellular carcinomaFuture Oncology20204
22Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT studyJournal of Heart and Lung Transplantation20224
23Aorto‐Peripheral MDCT Angiography: Implications for Contrast Medium DeliveryImaging Decisions (Berlin, Germany)20083
24Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancerAnnals of Oncology20193
25Switching from PDE5i to Riociguat in the RESPITE Study: Effect on Right Heart FunctionJournal of Heart and Lung Transplantation20182
26Validation of REVEAL Risk Score Calculator 2.0 in Patients with CTEPH in the Phase III CHEST StudyJournal of Heart and Lung Transplantation20202
27400P Impact of regorafenib dose optimization on comparative outcomes in the treatment of relapsed/refractory metastatic colorectal cancer (mCRC)Annals of Oncology20222
28Application of the REVEAL risk score calculator 2.0 in the CHEST studyRespiratory Medicine20221
29Mirena(R) removal from a nulliparous woman: response from Bayer HealthCareJournal of Family Planning and Reproductive Health Care20110
30Abstract No. 196: Worldwide trends in locoregional therapy (LRT) for hepatocellular carcinoma (HCC): 2nd interim analysis (IA; 1500 patients [pts]) of the GIDEON (global investigation of therapeutic decisions in HCC and of its treatment with sorafenib) studyJournal of Vascular and Interventional Radiology20120
31Pharmaceutical Medicine in the Emerging MarketsJournal of Vascular and Interventional Radiology20130
32Global GIDEON data: Subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinomaAnnals of Oncology20160
33Validation of REVEAL Risk Score Calculator 2.0 in Patients with PAH in the Phase III PATENT StudyJournal of Heart and Lung Transplantation20200
34Switching to Riociguat from Phosphodiesterase-5 Inhibitors, With or Without Endothelin Receptor Antagonists, in Patients with Pulmonary Arterial Hypertension: Results from the REPLACE StudyJournal of Heart and Lung Transplantation20210
35Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registryJournal of Heart and Lung Transplantation20170
36Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE studyJournal of Heart and Lung Transplantation20170